Here’s to why Cara Therapeutics Inc. (CARA) stock rises during after-market?


Cara Therapeutics Inc. (NASDAQ: CARA) stock gained by 4.23% at last close while the CARA stock price surges by 26.05% in the after-hours trading session. Cara Therapeutics is a clinical-stage pharmaceutical business focusing on discovering and selling novel chemical entities that address peripheral kappa opioid receptors, or KORs, to relieve pruritus.

>> 7 Top Picks for the Post-Pandemic Economy << 

CARA stock Significant Development

KORSUVA (difelikefalin) for injection has been authorized by the US Food and Drug Administration to treat mild-to-severe pruritus linked with chronic kidney disease in people receiving hemodialysis, according to Cara Therapeutics. KORSUVA injectable is a first-in-class kappa opioid receptor (KOR) agonist for the peripheral nervous system. The FDA granted Priority Review to the KORSUVA injectable new drug application (NDA). It is contingent on the fact that, if authorized, the therapy will provide significant advances in the safety or efficacy of the treatment, diagnosis, or prevention of severe diseases when compared to existing treatments.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Read More

Positive findings from two key Phase 3 trials – KALM-1, conducted in the United States (New England Journal of Medicine 2020; 382:222-232), and the worldwide KALM-2 – as well as supporting data from an additional 32 clinical investigations, led to its clearance. The injection of KORSUVA was typically well-tolerated.


In the United States, Vifor Pharma and Cara have signed to an exclusive license to sell KORSUVA. In non-Fresenius Medical Care clinics in the United States, that deal includes a 60 percent Cara, 40 percent Vifor Pharma profit-sharing structure. Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics previously agreed to offer KORSUVA injectable to Fresenius Medical Care North America dialysis clinics in the United States under a Cara 50%, Vifor Pharma 50% profit-sharing deal.

>> 7 Top Picks for the Post-Pandemic Economy << 

To guarantee prompt reimbursement and patient access to KORSUVA injectable, Vifor Pharma and Cara Therapeutics are in the process of submitting the appropriate documents to the US Centers for Medicare and Medicaid Services. Vifor Pharma anticipates starting to promote KORSUVA Injection in Q1 2022, with reimbursement expected in H1 2022, depends on CMS timeline.


Please enter your comment!
Please enter your name here